drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (biological)
drug_description
Autologous patient T cells genetically engineered to express a chimeric antigen receptor targeting glypican-2 (GPC2) for treatment of relapsed/refractory high-risk neuroblastoma and metastatic retinoblastoma; CAR engagement induces T-cell activation, cytokine release, and cytotoxic killing of GPC2-positive tumor cells, including stem-like compartments.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a chimeric antigen receptor targeting glypican-2 (GPC2). CAR binding to GPC2 activates CD3zeta and costimulatory signaling, leading to T-cell activation, cytokine release, proliferation, and targeted cytotoxic killing of GPC2-positive tumor cells (neuroblastoma/retinoblastoma), including stem-like compartments.
drug_name
GPC2 CAR T cells
nct_id_drug_ref
NCT05650749